Madrigal Pharmaceuticals
MDGL
84 hedge funds and large institutions have $119M invested in Madrigal Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 34 increasing their positions, 25 reducing their positions, and 18 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 97 → 84 (-13)
20% less capital invested
Capital invested by funds: $148M → $119M (-$29M)
41% less call options, than puts
Call options by funds: $412K | Put options by funds: $701K
72% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$4.12M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$728K |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$657K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$447K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$395K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
-$892K |
| 2 |
Norges Bank
Oslo,
Norway
|
-$836K |
| 3 |
SIP
Stoneridge Investment Partners
Radnor,
Pennsylvania
|
-$533K |
| 4 |
Bank of New York Mellon
New York
|
-$312K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
-$294K |
MDGL Hedge Fund Activity: Q3 2015 in Review
84 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q3 2015, worth a combined $119M — down 20% from $148M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of MDGL and 5 opened new positions — a net loss of 13 holders — while 25 trimmed existing stakes and 34 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $4.12M. The largest seller was Catalyst Capital Advisors, exiting entirely with an estimated $892K sold.
- 84 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q3 2015, down from 97 in Q2 2015.
- Funds reported $119M of Madrigal Pharmaceuticals stock for Q3 2015, down 20% quarter-over-quarter.
- 5 funds opened new Madrigal Pharmaceuticals positions in Q3 2015 and 18 closed out, a net change of -13 holders.
- The largest Madrigal Pharmaceuticals buyer in Q3 2015 was Armistice Capital, an estimated $4.12M added.
- The largest Madrigal Pharmaceuticals seller in Q3 2015 was Catalyst Capital Advisors, an estimated $892K sold.
Based on aggregated 13F filings for Q3 2015.